N. Baryawno

This study identifies circadian gene network disruption in high-risk neuroblastoma across multiple biological contexts, showing it is a network-level alteration rather than a single-gene effect.

This study identifies a thymic mesenchymal niche cell subset that supports T cell regeneration and shows its therapeutic potential in reversing thymic atrophy.

The paper identifies a transcriptional signature in primary ccRCC tumors that predicts metastatic potential and patient survival.

This study uses single-cell and spatial transcriptomic analyses to characterize the prostate tumor microenvironment, revealing immune suppression and high angiogenic activity.

This study identifies DHODH as a prognostic marker and therapeutic target in neuroblastoma, showing its inhibition improves survival in preclinical models and suggests combination therapy with temozolomide.

This study identifies PPM1D as an oncogene and therapeutic target in neuroblastoma by showing its role in p53 inactivation and tumor growth.

The paper identifies a subpopulation of malignant Schwann cell precursor-like cells in neuroblastoma that connects adrenergic and mesenchymal tumor cells, suggesting intratumoral plasticity mechanisms.

The paper identifies an immunosuppressive microenvironment in human prostate cancer bone metastases and shows that disrupting the CCL20-CCR6 axis can restore T cell reactivity and improve survival in mice.

The paper defines a cellular taxonomy of mouse bone marrow stroma using single-cell RNA-seq and shows how leukemia disrupts stromal function to impair normal hematopoiesis.